Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Inclusion Criteria: * Females or males with histologic confirmation of breast carcinoma and diagnosis of metastatic breast adenocarcinoma * Confirmed HER2 amplification by immunohistochemical staining (IHC) 3+ or FISH amplified (either primary or metastatic). * Have had any number of prior HER2 targeted therapy containing chemotherapies for treatment of breast cancer * Measurable extent of disease * Life expectancy of 3 months or greater * Patients must have adequate heart function, determined with ECHO or MUGA (ECHO preferred). * Patients must have adequate bone marrow and organ function * Patient of childbearing potential must be willing to use an effective means of contraception during their participation on trial * Greater than 3 weeks from prior radiation or chemotherapy; more than 1 week from prior hormonal therapy; and more than 6 weeks from prior treatment with nitrosoureas or mitomycin. * No serious intercurrent medical illness. * Controlled metastatic CNS disease ≥ 3 months * The ability to understand and willingness to sign a written informed consent form, and to comply with the protocol. Exclusion Criteria: * Pregnant or nursing women * Patients who are poor medical risk because of other non-malignant systemic disease or active, uncontrolled infection. * Prior craniospinal radiation, or total body irradiation (TBI). * Patients receiving G-CSF (filgrastim or pegfilgrastim) or thrombopoietin (or other platelet growth factors) within the 3 weeks prior to enrollment (erythropoietin is allowed). * Prior chemotherapy within the last 3 weeks (last 6 weeks for nitrosureas/mitomycin). * Prior radiation therapy within the last 3 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation). * Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. * Current symptoms of angina or uncontrolled arrhythmias, uncontrolled hypertension with systolic blood pressure \>=170 or diastolic blood pressure \>=110. * Psychiatric illness precluding participation in study * Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest. * Carcinomatous meningitis or CNS mets not controlled for ≥ 3 months.